A Randomized, Open-Label, Parallel Group Comparative Study of Paliperidone Palmitate (50, 100, 150 mg eq) and Risperidone LAI (25, 37.5, or 50 mg) in Subjects With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Paliperidone (Primary) ; Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Xian-Janssen
- 06 Jun 2010 Results were presented at the 27th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
- 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jun 2009 Actual patient number (452) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History